SP Elixir (OPC) Private Limited

Exemptia 40mg Adalimumab Injection is a biological medication used to treat a variety of autoimmune conditions. Adalimumab is a monoclonal antibody that works by targeting and inhibiting tumor necrosis factor-alpha (TNF-α), a substance in the body that contributes to inflammation in certain diseases.

Key Information:

• Active Ingredient: Adalimumab.
• Class: TNF inhibitor (biologic).
• Mechanism of Action: Adalimumab works by binding to TNF-α, a protein that plays a central role in the inflammation process. By inhibiting TNF-α, it helps to reduce inflammation, swelling, and pain in conditions where the immune system is overactive.

Common Uses:

1. Rheumatoid Arthritis: Used to reduce inflammation, pain, and damage caused by rheumatoid arthritis, often in combination with other medications.
2. Psoriatic Arthritis: Helps to reduce symptoms of arthritis associated with psoriasis, improving joint function.
3. Crohn’s Disease: Used to reduce inflammation in the digestive tract in Crohn’s disease.
4. Ulcerative Colitis: Helps to reduce inflammation in the colon and rectum, treating symptoms of ulcerative colitis.
5. Ankylosing Spondylitis: Used to treat inflammation in the spine and joints in ankylosing spondylitis.
6. Plaque Psoriasis: Reduces the symptoms of plaque psoriasis, a condition where the immune system causes skin cells to build up rapidly.
7. Other Conditions: Can be used for juvenile idiopathic arthritis, ** hidradenitis suppurativa**, and uveitis (eye inflammation).

Administration:

• Subcutaneous Injection: Exemptia is typically administered as an injection under the skin (subcutaneously), usually in the abdomen or thigh. The injection may be given every two weeks or once a month, depending on the condition being treated and the specific treatment plan prescribed by the doctor.

Side Effects:

• Injection site reactions: Pain, redness, swelling, or irritation at the injection site.
• Increased risk of infections: Since adalimumab suppresses the immune system, it can increase the risk of serious infections like tuberculosis (TB), fungal infections, bacterial infections, or viruses.
• Headaches.
• Rashes or skin reactions.
• Nausea or vomiting.
• Fatigue.
• Liver problems: Monitor liver function during treatment.
• Blood disorders: Can cause changes in blood counts, including low white blood cells, red blood cells, or platelets.
• Increased risk of cancer: Long-term use of TNF inhibitors like adalimumab can slightly increase the risk of certain types of cancer, including lymphoma.

Adalimumab

Plamumab 40mg Injection contains Adalimumab, a monoclonal antibody used to treat various autoimmune diseases. Adalimumab works by inhibiting tumor necrosis factor (TNF-α), a protein involved in inflammation. By blocking TNF-α, it helps reduce inflammation and tissue damage associated with several inflammatory conditions.

Common Uses:

• Rheumatoid Arthritis: To reduce inflammation and slow down joint damage.
• Psoriatic Arthritis: To manage inflammation in the joints and skin.
• Crohn’s Disease: For controlling inflammation in the intestines.
• Ulcerative Colitis: To treat inflammation in the colon.
• Ankylosing Spondylitis: To reduce inflammation in the spine.
• Plaque Psoriasis: To treat skin lesions and improve quality of life.

Mechanism of Action:

Adalimumab is a TNF inhibitor that works by binding to TNF-α, preventing it from binding to its receptors and reducing the inflammatory response. This leads to decreased tissue damage and symptom relief.

Side Effects:

• Upper respiratory infections
• Headache
• Injection site reactions (pain, redness, swelling)
• Risk of infections due to immune system suppression
• Nausea or vomiting
• Increased risk of certain cancers (rare)

Administration:

• Plamumab is administered as an injection under the skin (subcutaneous), typically once every 2 weeks or as prescribed by the healthcare provider.

Regular monitoring for infections and other side effects is essential during treatment with Adalimumab.